Haploidentical Allogeneic Transplantation As Salvage in Relapsed Multiple Myeloma
Phyllis McKiernan(Hackensack University Medical Center), Michèle L. Donato(The University of Texas Health Science Center at Houston), Brenda Díaz(Hackensack University Medical Center), David S. Siegel(Hackensack Meridian Health), Themba Nyirenda(Hackensack University Medical Center), P. L. Sutherland(Hackensack University Medical Center), Melissa Baker(Hackensack University Medical Center), Joshua R. Richter(Hackensack University Medical Center), Scott D. Rowley(Johns Hopkins Hospital), David H. Vesole(Hackensack University Medical Center)
Cited by 3
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k